Anita Blanchard, OD
Optometrist · Franklinton, LANPI 1962636407
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 27.0% of the total. Reporting peaked in 2022 at $1,581 and has fallen 51.8% since, to $762 in 2025.
Across 177 payments — averaging $29.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Bausch & Lomb Americas Inc.$435
- Optos, Inc.$416
- Glaukos Corporation$346
- Tarsus Pharmaceuticals, Inc.$336
- Sun Pharmaceutical Industries Inc.$314
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,03697%
- Entertainment$1563%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 73 | $1,399 |
| Bausch & Lomb Americas Inc. | 12 | $435 |
| Optos, Inc. | 4 | $416 |
| Glaukos Corporation | 4 | $346 |
| Tarsus Pharmaceuticals, Inc. | 15 | $336 |
| Sun Pharmaceutical Industries Inc. | 13 | $314 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $307 |
| Oyster Point Pharma, Inc. | 11 | $300 |
| Kala Pharmaceuticals, Inc. | 5 | $183 |
| Dompe US, Inc. | 4 | $180 |
| Johnson & Johnson Vision Care, Inc. | 2 | $165 |
| Carl Zeiss Meditec USA, Inc. | 1 | $147 |
| Eyevance Pharmaceuticals LLC | 7 | $132 |
| Alcon | 6 | $120 |
| Mallinckrodt Hospital Products Inc. | 1 | $118 |
| Harrow Eye, LLC | 5 | $103 |
| Shire North American Group Inc | 2 | $86 |
| LKC Technologies, Inc. | 1 | $28 |
| Amgen | 1 | $23 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PANORAMIC OPHTHALMOSCOPE$502
- OCT OPHTHALMOSCOPE$381
- VUITY$342
- NFC-700$251
- INFUSE$248
- Acuvue$150
- CIRRUS HD-OCT$147
- KXL System$146
- Photrexa$146
- P200DTx$139
- P200T$139
- P200TE$139
- P200TxE$139
- RESTASIS MULTIDOSE$134
- ACTHAR$118
- ULTRA MULTIFOCAL TORIC$117
- XDEMVY$116
- BIOTRUE$112
- ULTRA$112
- BIOTRUE ONE DAY$112
How this compares
$5,192 in reported general payments places this provider in the 85th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 103 | $134,230 |
| LumiganBimatoprost | 226 | $112,847 |
| XdemvyLotilaner | 34 | $62,584 |
| XiidraLifitegrast | 13 | $19,597 |
| VevyeCyclosporine | 17 | $12,511 |
| Latanoprost | 390 | $5,245 |
| Prednisolone Acetate | 135 | $4,367 |
| RhopressaNetarsudil Mesylate | 11 | $3,291 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 182 | $2,976 |
| Brimonidine Tartrate | 37 | $2,308 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 37 | $1,706 |
| Timolol Maleate | 181 | $1,639 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 120 | $1,542 |
| ValacyclovirValacyclovir Hcl | 47 | $1,044 |
| MoxifloxacinMoxifloxacin Hcl | 39 | $691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $1,399 | $247,077329 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $336 | $62,58434 claims |
| Bausch & Lomb Americas Inc.Xiidra | $435 | $19,59713 claims |
| Harrow Eye, LLCVevye | $103 | $12,51117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 500 optometrist providers in Louisiana.
Other optometrist in Franklinton
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
- John McCallLogansport$32K
- Robert KellyMarrero$26K
- Shane FontenotJennings$23K
- Stephen LewisShreveport$17K
- Breanne McGheeNew Orleans$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.